从“治疗疾病”到“管理健康”:多囊卵巢综合征全生命周期健康管理模式的构建
From “Disease Treatment” to “Health Management”: Constructing a Lifespan Health Model for PCOS
DOI: 10.12677/tcm.2026.152076, PDF,    科研立项经费支持
作者: 黄亚玲*, 奉俊宏, 张 燕, 王 妍#:成都中医药大学附属医院妇科,四川 成都
关键词: 多囊卵巢综合征个性化干预全生命周期健康Polycystic Ovary Syndrome Personalized Intervention Lifespan Health
摘要: 多囊卵巢综合征(PCOS)是育龄期女性高发的慢性内分泌代谢性疾病,发病机制复杂且临床表现异质,不仅严重影响女性生殖健康,还与2型糖尿病、代谢综合征、子宫内膜癌等多种疾病的发生发展密切相关,对患者全生命周期的身心健康与生活质量构成持续性威胁。传统医疗模式多以育龄期女性生育需求为核心,易忽视其他年龄阶段患者的健康管理需求。基于此,本文创新性提出以PCOS患者不同生命阶段为核心的全生命周期健康管理模式,系统阐述育龄期无生育要求、围绝经期及绝经后期PCOS患者面临的核心挑战与健康风险,重点探讨各阶段的个性化管理策略,旨在通过精准化、连续性干预预防远期并发症,提升患者全生命周期生活质量,推动PCOS诊疗从疾病治疗向健康管理的模式转型。
Abstract: Polycystic ovary syndrome (PCOS) is a chronic endocrine and metabolic disorder highly prevalent among women of reproductive age. It is characterized by complex pathogenesis and heterogeneous clinical manifestations, which not only severely impact reproductive health but are also closely associated with the development and progression of various conditions such as type 2 diabetes, metabolic syndrome, and endometrial cancer. These factors pose a persistent threat to the physical and mental well-being and overall quality of life of patients throughout their lifespan. Traditional medical models have predominantly focused on addressing the fertility needs of reproductive-aged women, often overlooking the health management requirements of patients in other age groups. In response, this paper innovatively proposes a life-cycle health management model centered on the distinct stages of PCOS patients’ lives. It systematically elucidates the core challenges and health risks faced by PCOS patients with no immediate fertility demands, as well as those in the perimenopausal and postmenopausal stages. Furthermore, it emphasizes personalized management strategies tailored to each phase, aiming to prevent long-term complications through precise and continuous interventions, enhance the quality of life across patients’ entire lifespan, and facilitate a paradigm shift in PCOS care from disease treatment to holistic health management.
文章引用:黄亚玲, 奉俊宏, 张燕, 王妍. 从“治疗疾病”到“管理健康”:多囊卵巢综合征全生命周期健康管理模式的构建[J]. 中医学, 2026, 15(2): 74-81. https://doi.org/10.12677/tcm.2026.152076

参考文献

[1] Bozdag, G., Mumusoglu, S., Zengin, D., Karabulut, E. and Yildiz, B.O. (2016) The Prevalence and Phenotypic Features of Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Human Reproduction, 31, 2841-2855. [Google Scholar] [CrossRef] [PubMed]
[2] Teede, H.J., Tay, C.T., Laven, J., Dokras, A., Moran, L.J., Piltonen, T.T., et al. (2023) Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Obstetrical & Gynecological Survey, 78, 742-743. [Google Scholar] [CrossRef
[3] Kamboj, M.K. and Bonny, A.E. (2017) Polycystic Ovary Syndrome in Adolescence: Diagnostic and Therapeutic Strategies. Translational Pediatrics, 6, 248-255. [Google Scholar] [CrossRef] [PubMed]
[4] Milutinović, D.V., Macut, D., Božić, I., Nestorov, J., Damjanović, S. and Matić, G. (2011) Hypothalamic-Pituitary-Adrenocortical Axis Hypersensitivity and Glucocorticoid Receptor Expression and Function in Women with Polycystic Ovary Syndrome. Experimental and Clinical Endocrinology & Diabetes, 119, 636-643. [Google Scholar] [CrossRef] [PubMed]
[5] Rosenfield, R.L. and Ehrmann, D.A. (2023) The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The HPA Axis Hypothesis. Trends in Endocrinology & Metabolism, 34, 94-108.
[6] Mena, G.P., Mielke, G.I. and Brown, W.J. (2019) The Effect of Physical Activity on Reproductive Health Outcomes in Young Women: A Systematic Review and Meta-Analysis. Human Reproduction Update, 25, 542-564. [Google Scholar] [CrossRef] [PubMed]
[7] Lass, N., Kleber, M., Winkel, K., Wunsch, R. and Reinehr, T. (2011) Effect of Lifestyle Intervention on Features of Polycystic Ovarian Syndrome, Metabolic Syndrome, and Intima-Media Thickness in Obese Adolescent Girls. The Journal of Clinical Endocrinology & Metabolism, 96, 3533-3540. [Google Scholar] [CrossRef] [PubMed]
[8] 周惠芳, 洪艳丽, 刁飞扬, 等. 多囊卵巢综合征中西医结合诊疗指南(2024年版) [J]. 中医杂志, 2025, 66(6): 649-656.
[9] Al Khalifah, R.A., Florez, I.D., Dennis, B., Thabane, L. and Bassilious, E. (2016) Metformin or Oral Contraceptives for Adolescents with Polycystic Ovarian Syndrome: A Meta-Analysis. Pediatrics, 137, e20254089. [Google Scholar] [CrossRef] [PubMed]
[10] 中华医学会妇产科学分会内分泌学组及指南专家组. 多囊卵巢综合征中国诊疗指南[J]. 中华妇产科杂志, 2018, 53(1): 2-6.
[11] Lam, J., Steinke, D.T. and Willis, S.C. (2023) Teratogenic Drugs in Dermatology: A Comprehensive Review and Update for Clinical Practice. Journal of the American Academy of Dermatology, 89, 677-685.
[12] Franik, S. and Kremer, J.A. (2024) The Evolving Role of Letrozole in Ovulation Induction: From Second Line to First Line. Current Opinion in Obstetrics and Gynecology, 36, 155-160.
[13] Eisenhardt, S., Schwarzmann, N., Henschel, V., Germeyer, A., von Wolff, M., Hamann, A., et al. (2006) Early Effects of Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomized, Double-Blind, Placebo-Controlled Trial. The Journal of Clinical Endocrinology & Metabolism, 91, 946-952. [Google Scholar] [CrossRef] [PubMed]
[14] Vanky, E. and Løvvik, T.S. (2020) Polycystic Ovary Syndrome and Pregnancy—From a Clinical Perspective. Current Opinion in Endocrine and Metabolic Research, 12, 8-13. [Google Scholar] [CrossRef
[15] 金兰英, 季丽梅, 胡旻, 等. 左炔诺孕酮宫内缓释系统对多囊卵巢综合征患者生殖激素和代谢指标的影响[J]. 中国妇幼保健, 2025, 40(6): 1053-1057.
[16] 中国2型糖尿病防治指南(2020年版) [J]. 中国实用内科杂志, 2021, 41(8): 668-695.
[17] 马镇玲, 赵玮, 甘肖梅. 饮食调节联合有氧运动治疗肥胖型多囊卵巢综合征的效果[J]. 中外医学研究, 2020, 18(5): 161-163.
[18] 中华医学会妇产科学分会妇科内分泌学组. 多囊卵巢综合征长期管理中国专家共识[J]. 中华妇产科杂志, 2020, 55(11): 721-727.
[19] Glintborg, D., Rubin, K.H., Nybo, M., Abrahamsen, B. and Andersen, M. (2018) Cardiovascular Disease in a Nationwide Population of Danish Women with Polycystic Ovary Syndrome. Cardiovascular Diabetology, 17, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
[20] Spremović Rađenović, S., Pupovac, M., Andjić, M., Bila, J., Srećković, S., Gudović, A., et al. (2022) Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). Biomedicines, 10, Article 131. [Google Scholar] [CrossRef] [PubMed]
[21] Zhu, T., Cui, J. and Goodarzi, M.O. (2021) Polycystic Ovary Syndrome and Risk of Type 2 Diabetes, Coronary Heart Disease, and Stroke. Diabetes, 70, 627-637. [Google Scholar] [CrossRef] [PubMed]
[22] 中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南2023版[J]. 中华妇产科杂志, 2023, 58(1): 4-21.
[23] North American Menopause Society (2022) Menopause Practice: A Clinical Guidebook. 5th Edition, North American Menopause Society.
[24] 中国医师协会心血管内科医师分会女医师工作委员会, 中华医学会心血管病学分会女性心脏健康学组. 中国女性心血管疾病预防专家共识[J]. 中华内科杂志, 2017, 56(6): 472-476.
[25] Matevossian, K. and Carpinello, O. (2021) Polycystic Ovary Syndrome: Menopause and Malignancy. Clinical Obstetrics & Gynecology, 64, 102-109. [Google Scholar] [CrossRef] [PubMed]
[26] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J]. 中国癌症杂志, 2021, 31(10): 954-1040.
[27] 陈静红, 尹如铁. 2023年欧洲肿瘤内科学会《新诊断和复发性上皮性卵巢癌的诊断、治疗和随访临床实践指南》解读[J]. 实用妇产科杂志, 2024, 40(2): 116-121.
[28] 史晓林, 刘康. 老年性骨质疏松症中西医结合诊疗指南[J]. 中国骨质疏松杂志, 2024, 30(7): 937-946.
[29] 中华医学会内分泌学分会. 原发性骨质疏松症诊疗指南(2023版) [J]. 中华内分泌代谢杂志, 2023, 39(3): 177-260.